Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effects of Local Vibrations Program of Dorsiflexor Muscles on Neuromotor Recovery in Subacute Stroke Patients.

NCT05945212 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-03-12
Last updated
2026-10-09

Condition(s) studied

Stroke Rehabilitation

Investigational drug(s) / intervention(s)

VibrationSham vibration10 meters Walk Test2 Minute Walk Test (2MWT)Fugl-Meyer (FMA-LE)Modified Ashworth scaleABILOCO questionnaireBarthel indexisometric ergometerElectromyograms (EMG)Traditional quantified gait analysisSPM - Statistical Parametric MappingFACIT questionnaire (Functional Assessment of Chronic Illness Therapy)

Vibration: The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz

Sham vibration: The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.

10 meters Walk Test: Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.

2 Minute Walk Test (2MWT): Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.

Fugl-Meyer (FMA-LE): The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34

Modified Ashworth scale: The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4

ABILOCO questionnaire: The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)

Barthel index: The Barthel index measure autonomy in daily life.

isometric ergometer: Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.

Electromyograms (EMG): Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.

Traditional quantified gait analysis: Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.

SPM - Statistical Parametric Mapping: Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.

FACIT questionnaire (Functional Assessment of Chronic Illness Therapy): A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.

Study summary

The aim of the vibration intervention proposed in the current study is to allow a better neuromotor recovery in subacute stroke patients when compared with standard rehabilitation alone. These last years, it has been proven that the solicitation of a muscle using vibrations may lead to positive effects on the neuromuscular function. Thus, the aim of the current study is to assess if the addition to a standard rehabilitation program of local vibrations sessions of the dorsiflexor muscles of the paretic limb of stroke patients may allow a better recovery of walking speed (primary outcome). One group using vibrations (i.e. experimental group) and one group with sham vibration (i.e. control group) will take part to this study.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Stroke patients in subacute rehabilitation phase (between 14 days and 3 months post-stroke) * Presenting with a stroke, ischemic or hemorrhagic * Lower-limb deficiency with an initial motor testing \< 4 according to the MRC scale * No neurological history with functional impact other than stroke * Having received informed information about the study and having signed the written consent * Affiliated or entitled to a social security scheme. * Patients under guardianship may be included; they may give their consent with the assistance of their guardian. If the participant is unable to write, their consent may be given and documented by other appropriate means in the presence of at least one impartial witness. In this case, the witness will sign and date the informed consent document. Exclusion Criteria: * Multiple stroke * Other neurological, cognitive or psychiatric conditions * Orthopedic ankle history compromising measurements * Botulinum toxin injected in the lower limb prior the study protocol * Patient with phlebitis or risk of thrombosis in the lower limb * Patient under tutorship

Primary outcome measure(s)

  • Gait speed by 10 meters Walk Test (in meter /second) results — Month 2
    Analysis Gait speed by 10 meters Walk Test (in meter /second) results

Trial sites (7)

FacilityCityRegionStatus
Centre Hospitalier Georges Claudinon Le Chambon-Feugerolles France Not Yet Recruiting
Hôpital Marrel Rive-de-Gier France Recruiting
Centre Hospitalier de Roanne Roanne France Not Yet Recruiting
Service de SSR Val-Rosay Saint-Didier-au-Mont-d'Or France Not Yet Recruiting
Hôpital Bellevue, CHU de Saint-etienne Saint-Etienne France Recruiting
Service de SSR du Centre Le Clos Champirol Saint-Etienne France Not Yet Recruiting
Hospices Civils de Lyon, site Henry Gabrielle Saint-Genis-Laval France Not Yet Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05945212 on ClinicalTrials.gov ↗ ← All trials in France